Virus-specific T cells as a platform for solid tumor immunotherapy

16 August 2019

In this video, Chief Scientific Officer Dr. John Connolly presents Tessa Therapeutics' work in tackling the current challenges in cell therapy for aggressive tumors. This work focuses on the study and use of virus-specific T cells (VSTs) as a platform to deliver an effective and durable anti-tumor immune response. This presentation took place at ACEA Biosciences’ 7th Annual Cancer and Immunotherapy symposium in Atlanta.

Discover more about this research in SelectScience's exclusive interview with Dr. John Connolly here>>